Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Since we began operations in November 2014, we have built a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
Corvus Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference 201702/27/17
Corvus Pharmaceuticals Announces Expansion of Renal Cell Carcinoma Cohort in Ongoing Phase 1/1b Clinical Study of Lead Checkpoint Inhibitor CPI-44401/10/17
Corvus Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference 201701/04/17
There are currently no events scheduled.